{"transactions":[{"id":685632,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":322465,"price":25,"value":8061625.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":428946,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685631,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":478377,"price":25,"value":11959425.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":567358,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685630,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":1359674,"price":25,"value":33991850.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2441454,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685629,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":63643,"price":26.2,"value":1667446.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":751411,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685628,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":94415,"price":26.2,"value":2473673.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1045735,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685627,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":268354,"price":26.2,"value":7030874.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3801128,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":712696,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":23.61,"value":118050.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.50 to $23.794 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2962,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712695,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":11665,"price":23.62,"value":275527.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":815054,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712694,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":49193,"price":23.17,"value":1139801.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":826719,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712693,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":14844,"price":23.62,"value":350615.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1140150,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712692,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":62543,"price":23.17,"value":1449121.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1154994,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712691,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":29587,"price":23.62,"value":698844.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4069482,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712690,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":124379,"price":23.17,"value":2881861.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4099069,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712689,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":100019,"price":22.79,"value":2279433.01,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":875912,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712688,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":127182,"price":22.79,"value":2898477.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1217537,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712687,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":253039,"price":22.79,"value":5766758.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4223448,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":722899,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":40702,"price":21.14,"value":860440.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":975931,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722898,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":51756,"price":21.14,"value":1094121.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1344719,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722897,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":102969,"price":21.14,"value":2176764.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4476487,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722896,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":64411,"price":21.28,"value":1370666.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1016633,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722895,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":81903,"price":21.28,"value":1742895.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1396475,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722894,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":162954,"price":21.28,"value":3467661.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4579456,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":725573,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":5019,"price":21.1,"value":105900.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1081044,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725572,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":6382,"price":21.1,"value":134660.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1478378,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725571,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":12699,"price":21.1,"value":267948.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4742410,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725570,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":19973,"price":21.02,"value":419832.46,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1086063,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725569,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":25397,"price":21.02,"value":533844.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1484760,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725568,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":50530,"price":21.02,"value":1062140.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4755109,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725567,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":30774,"price":21.13,"value":650254.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1106036,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725566,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":39131,"price":21.13,"value":826838.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1510157,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725565,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":77855,"price":21.13,"value":1645076.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4805639,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":744760,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:13:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264022","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264022/ownership.xml","form_type":"4"}},{"id":790022,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":17244,"price":18.18,"value":313495.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1136810,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790021,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":428,"price":18.18,"value":7781.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7962,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790020,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":43621,"price":18.18,"value":793029.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4883494,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790019,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":21926,"price":18.18,"value":398614.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1549288,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790018,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":2403,"price":18.03,"value":43326.09,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1154054,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790017,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":60,"price":18.03,"value":1081.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8390,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790016,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":6081,"price":18.03,"value":109640.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4927115,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790015,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":3056,"price":18.03,"value":55099.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1571214,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790014,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":2466,"price":18,"value":44388.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1156457,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790013,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":61,"price":18,"value":1098.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8450,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790012,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":6241,"price":18,"value":112338.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4933196,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790011,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":3136,"price":18,"value":56448.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1574270,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":796967,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":21,"price":19,"value":399.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1158923,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796966,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1,"price":19,"value":19.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8511,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796965,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":52,"price":19,"value":988.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4939437,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796964,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":26,"price":19,"value":494.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1577406,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796963,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":47082,"price":18.38,"value":865367.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1158944,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796962,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1170,"price":18.38,"value":21504.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8512,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796961,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":119115,"price":18.38,"value":2189333.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4939489,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796960,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":59870,"price":18.38,"value":1100410.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1577432,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":800097,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":35947,"price":18.15,"value":652438.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1206026,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800096,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":894,"price":18.15,"value":16226.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":9682,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800095,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":90943,"price":18.15,"value":1650615.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5058604,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800094,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":45709,"price":18.15,"value":829618.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1637302,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800093,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":28583,"price":18.48,"value":528213.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1241973,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800092,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":710,"price":18.48,"value":13120.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":10576,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800091,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":72310,"price":18.48,"value":1336288.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5149547,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800090,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":36345,"price":18.48,"value":671655.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1683011,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800089,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":15148,"price":19.19,"value":290690.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1270556,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800088,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":377,"price":19.19,"value":7234.63,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":11286,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800087,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":38322,"price":19.19,"value":735399.18,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5221857,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800086,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":19261,"price":19.19,"value":369618.59,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1719356,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":802960,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":59663,"price":19.68,"value":1174167.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1285704,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802959,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":1485,"price":19.68,"value":29224.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":11663,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802958,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":150942,"price":19.68,"value":2970538.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5260179,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802957,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":75866,"price":19.68,"value":1493042.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1738617,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802956,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":605,"price":20.05,"value":12130.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1345367,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802955,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":15,"price":20.05,"value":300.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":13148,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802954,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":1530,"price":20.05,"value":30676.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5411121,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802953,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":769,"price":20.05,"value":15418.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1814483,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802952,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":56228,"price":19.51,"value":1097008.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1345972,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802951,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":1398,"price":19.51,"value":27274.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":13163,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802950,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":142253,"price":19.51,"value":2775356.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5412651,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802949,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":71499,"price":19.51,"value":1394945.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1815252,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802948,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":56368,"price":20.06,"value":1130742.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1402200,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802947,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":1401,"price":20.06,"value":28104.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":14561,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802946,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":142604,"price":20.06,"value":2860636.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5554904,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":802945,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T22:27:22.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":71676,"price":20.06,"value":1437820.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1886751,"source":{"system":"sec-edgar","filing":"0001577014-26-000002","document":"form4-04222026_100417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/form4-04222026_100417.xml","form_type":"4"}},{"id":914058,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914057,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914056,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1920,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":61.9,"underlying":"Common Stock","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914055,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":265.9,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914054,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":190,"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914053,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914052,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":60,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914051,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":116693,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":914050,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:41:00.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":711193,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012195","document":"tm265471-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000110465926012195/tm265471-10_4seq1.xml","form_type":"4"}},{"id":1119187,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:05:16.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015956","document":"form4-06062025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000141588925015956/form4-06062025_040601.xml","form_type":"4"}},{"id":1125256,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-04T01:39:24.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":35000,"derivative":{"exercise_price":11.96,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-081356","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025081356/ownership.xml","form_type":"4"}},{"id":1291936,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-29T21:15:05.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":1111111,"price":13.5,"value":14999998.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1958427,"source":{"system":"sec-edgar","filing":"0001415889-25-002264","document":"form4-01292025_040102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588925002264/form4-01292025_040102.xml","form_type":"4"}},{"id":1361903,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T22:31:47.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":72,"price":33.1,"value":2383.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":847316,"source":{"system":"sec-edgar","filing":"0001415889-24-027119","document":"form4-11182024_101143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924027119/form4-11182024_101143.xml","form_type":"4"}},{"id":1361902,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T22:31:47.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":123,"price":33.1,"value":4071.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1458568,"source":{"system":"sec-edgar","filing":"0001415889-24-027119","document":"form4-11182024_101143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924027119/form4-11182024_101143.xml","form_type":"4"}},{"id":1361901,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T22:31:47.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":4,"price":33.1,"value":132.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":15962,"source":{"system":"sec-edgar","filing":"0001415889-24-027119","document":"form4-11182024_101143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924027119/form4-11182024_101143.xml","form_type":"4"}},{"id":1361900,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T22:31:47.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":583,"price":33.1,"value":19297.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5697508,"source":{"system":"sec-edgar","filing":"0001415889-24-027119","document":"form4-11182024_101143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924027119/form4-11182024_101143.xml","form_type":"4"}},{"id":1484498,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:05:29.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016187","document":"form4-06102024_040621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577014/000141588924016187/form4-06102024_040621.xml","form_type":"4"}},{"id":1502165,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-24T21:10:13.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":25133,"derivative":{"exercise_price":31.53,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":25133},"source":{"system":"sec-edgar","filing":"0000950170-24-064725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064725/ownership.xml","form_type":"4"}},{"id":1597107,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T22:08:16.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":17099,"price":30.05,"value":513824.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":847388,"source":{"system":"sec-edgar","filing":"0001415889-24-006766","document":"form4-03052024_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924006766/form4-03052024_100311.xml","form_type":"4"}},{"id":1597106,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T22:08:16.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":29435,"price":30.05,"value":884521.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The reporting person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1458691,"source":{"system":"sec-edgar","filing":"0001415889-24-006766","document":"form4-03052024_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000141588924006766/form4-03052024_100311.xml","form_type":"4"}}],"next_cursor":"2024-03-05T22:08:16.000000Z,1597106"}